nach oben

Endocrine

Erschienen in:

01.02.2013 | Original Article

A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population

verfasst von: Su Kang Kim, Hae Jeong Park, Il Ki Hong, Joo-Ho Chung, Young Gyu Eun

Erschienen in: Endocrine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Toll-like receptors (TLRs) are important components of innate immune response. The aim of this study was to investigate whether TLR gene cluster (TLR10-TLR1-TLR6) polymorphisms are associated with the etiology of papillary thyroid carcinoma (PTC) and its clinicopathologic characteristics. We recruited 94 PTC patients and 325 control subjects. Genotypes for each SNP were determined by direct sequencing. SNPStats and SPSS 18.0 were used to evaluate odds ratios (ORs), 95 % confidence intervals (CIs), and P values. Multiple logistic regression analyzes of genetic data were performed. The missense SNP rs11466653 was associated with small tumor size (<1 cm) in PTC. The frequency of the rs11466653 T allele was higher in PTC patients with tumors <1 cm in size than in the control group (95.8 vs. 87.2 %; P = 0.021, OR = 0.30, 95 % CI = 0.11–0.83). The T allele of rs11466653 (T/C, Met326Thr) in TLR10 may be a risk factor for the development of tumors in PTC in the Korean population.

K.W. Jung, S. Park, H.J. Kong, Y.J. Won, J.Y. Lee, H.G. Seo, J.S. Lee, Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res. Treat. 44, 11–24 (2012)PubMedCrossRef

A.Y. Chen, A. Jemal, E.M. Ward, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115, 3801–3807 (2009)PubMedCrossRef

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009)PubMedCrossRef

M.G. Borrello, L. Alberti, A. Fischer, D. Degl’innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, S. Pilotti, G. Cassinelli, P. Bressan, L. Fugazzola, A. Mantovani, M.A. Pierotti, Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl Acad. Sci. USA 102, 14825–14830 (2005)PubMedCrossRef

A. Pellegrini, N. Guinazu, L. Giordanengo, R.C. Cano, S. Gea, The role of toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan. Future Microbiol. 6, 1521–1533 (2011)PubMedCrossRef

N. Dalgic, D. Tekin, Z. Kayaalti, T. Soylemezoglu, E. Cakir, B. Kilic, B. Kutlubay, M. Sancar, M. Odabasi, Arg753Gln polymorphism of the human toll-like receptor 2 gene from infection to disease in pediatric tuberculosis. Hum. Immunol. 72, 440–445 (2011)PubMedCrossRef

N.S. Palikhe, S.H. Kim, J.H. Kim, P. Losol, Y.M. Ye, H.S. Park, Role of toll-like receptor 3 variants in aspirin-exacerbated respiratory disease. Allergy Asthma Immunol. Res. 3, 123–127 (2011)PubMedCrossRef

M.L. Sales, R. Schreiber, M.C. Ferreira-Sae, M.N. Fernandes, C.S. Piveta, J.A. Cipolli, C.C. Cardoso, J.R. Matos-Souza, B. Geloneze, K.G. Franchini, W. Nadruz Jr, Toll-like receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am. J. Hypertens. 23, 649–654 (2010)PubMedCrossRef

F.A. Castro, A. Forsti, S. Buch, H. Kalthoff, C. Krauss, M. Bauer, J. Egberts, B. Schniewind, D.C. Broering, S. Schreiber, M. Schmitt, J. Hampe, K. Hemminki, C. Schafmayer, TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur. J. Cancer 47, 1203–1210 (2011)PubMedCrossRef

10.

Z. Vidas, Polymorphisms in toll-like receptor genes—implications for prostate cancer development. Coll. Antropol. 34, 779–783 (2010)PubMed

11.

U. Hasan, C. Chaffois, C. Gaillard, V. Saulnier, E. Merck, S. Tancredi, C. Guiet, F. Briere, J. Vlach, S. Lebecque, G. Trinchieri, E.E. Bates, Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 174, 2942–2950 (2005)PubMed

12.

T. Chuang, R.J. Ulevitch, Identification of hTLR10: a novel human toll-like receptor preferentially expressed in immune cells. Biochim. Biophys. Acta 1518, 157–161 (2001)PubMedCrossRef

13.

R. Medzhitov, P. Preston-Hurlburt, C.A. Janeway Jr, A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 388, 394–397 (1997)PubMedCrossRef

14.

X. Du, A. Poltorak, Y. Wei, B. Beutler, Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. 11, 362–371 (2000)PubMed

15.

O. Takeuchi, T. Kawai, P.F. Muhlradt, M. Morr, J.D. Radolf, A. Zychlinsky, K. Takeda, S. Akira, Discrimination of bacterial lipoproteins by toll-like receptor 6. Int. Immunol. 13, 933–940 (2001)PubMedCrossRef

16.

O. Takeuchi, S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R.L. Modlin, S. Akira, Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169, 10–14 (2002)PubMed

17.

A. Ozinsky, D.M. Underhill, J.D. Fontenot, A.M. Hajjar, K.D. Smith, C.B. Wilson, L. Schroeder, A. Aderem, The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl Acad. Sci. USA 97, 13766–13771 (2000)PubMedCrossRef

18.

S. Janssens, R. Beyaert, Role of toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 16, 637–646 (2003)PubMedCrossRef

19.

S. Lindstrom, D.J. Hunter, H. Gronberg, P. Stattin, F. Wiklund, J. Xu, S.J. Chanock, R. Hayes, P. Kraft, Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol. Biomarkers Prev. 19, 873–876 (2010)PubMedCrossRef

20.

S.L. Zheng, K. Augustsson-Balter, B. Chang, M. Hedelin, L. Li, H.O. Adami, J. Bensen, G. Li, J.E. Johnasson, A.R. Turner, T.S. Adams, D.A. Meyers, W.B. Isaacs, J. Xu, H. Gronberg, Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res. 64, 2918–2922 (2004)PubMedCrossRef

21.

J. Sun, F. Wiklund, S.L. Zheng, B. Chang, K. Balter, L. Li, J.E. Johansson, G. Li, H.O. Adami, W. Liu, A. Tolin, A.R. Turner, D.A. Meyers, W.B. Isaacs, J. Xu, H. Gronberg, Sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl. Cancer Inst. 97, 525–532 (2005)PubMedCrossRef

22.

M. Canadas Garre, M. Lopez de la Torre Casares, P. Becerra Massare, M.A. Lopez Nevot, J. Villar Del Moral, N. Munoz Perez, R. Vilchez Joya, R. Montes Ramirez, J.M. Llamas Elvira, BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. Endocrinol. Nutr. 58, 175–184 (2011)PubMedCrossRef

23.

R. Iuliano, D. Palmieri, H. He, A. Iervolino, E. Borbone, P. Pallante, A. Cianflone, R. Nagy, H. Alder, G.A. Calin, F. Trapasso, C. Giordano, C.M. Croce, A. de la Chapelle, A. Fusco, Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr. Relat. Cancer 17, 1001–1006 (2010)PubMedCrossRef

24.

A. Salajegheh, R.A. Smith, K. Kasem, V. Gopalan, M.R. Nassiri, R. William, A.K. Lam, Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur. J. Surg. Oncol. 37, 93–99 (2011)PubMedCrossRef

25.

N. Kurtulmus, M. Duren, U. Ince, M. Cengiz Yakicier, O. Peker, O. Aydin, E. Altiok, S. Giray, H. Azizlerli, BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42, 404–410 (2012)

26.

M.P. Purdue et al., A pooled investigation of toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 30, 275–281 (2009)PubMedCrossRef

27.

V.L. Stevens, A.W. Hsing, J.T. Talbot, S.L. Zheng, J. Sun, J. Chen, M.J. Thun, J. Xu, E.E. Calle, C. Rodriguez, Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int. J. Cancer 123, 2644–2650 (2008)PubMedCrossRef

Titel: A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population
verfasst von: Su Kang Kim
Hae Jeong Park
Il Ki Hong
Joo-Ho Chung
Young Gyu Eun
Publikationsdatum: 01.02.2013
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9783-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Renaissance of acromegaly after bariatric surgery

Celiac disease in subjects with type 1 diabetes mellitus: a prevalence study in western Sicily (Italy)

Role of mineralocorticoid receptors on the hypothalamus–pituitary–adrenal axis in humans

Coronary microvascular function in patients with Cushing’s syndrome

A novel formulation of l-thyroxine (l-T4) reduces the problem of l-T4 malabsorption by coffee observed with traditional tablet formulations

Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide